Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies plan to bring into phase 2/3 trials to test in patients with early Alzheimer's disease.

Lilly has said that its drug has advantages over Leqembi ... very meaningful results for people with early symptomatic Alzheimer's disease and can now help to improve the standard of care for ...

Lilly’s neurodegeneration portfolio is anchored by the Alzheimer’s drug Kisunla, which received FDA approval last July. That antibody drug was internally discovered and developed within Lilly.

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, raised a $130 million Series B round.

Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

By improving insulin sensitivity and potentially interacting with receptors involved in learning and brain cell protection, semaglutide could potentially slow the progression of Alzheimer's disease.